HESTERBIOBSEHESTER BIOSCIENCES LTD· Pharmaceuticals & BiotechnologyHighNeutral
Announced Thu, 30 Jul, 2026 · 11:35 IST

Hester Biosciences Q1 FY27: Standalone PAT up 88%, Consolidated PAT up 459%

Revenue DeclinePat Growth 25pctEbitda Margin ExpansionExceptional ItemResults View source PDFExplain this filing

HESTERBIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-0.5%Reaction day
₹2495.00
prior close
₹2579.80
announcement price
In-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-0.6%+0.0% vs market
Pharmaceuticals peers, median of 162sector-0.8%+0.3% vs sector

On the reaction day the stock moved in line with Nifty Microcap 250 and 0.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+1.2
10m
+0.1
15m
+0.2
30m
-0.3
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-0.5-0.6+0.0-0.8+0.3
Next day
-1.7+0.5-2.2-0.5-1.2
2d
-2.9+1.9-4.7+0.2-3.1
3d
-0.6+2.3-2.9+0.1-0.7
4d
-2.0+3.6-5.6+0.5-2.5
5d
-1.0+4.0-5.0+0.7-1.7
1w
+0.2+4.0-3.8+1.4-1.2
15d
-3.6+4.9-8.4+0.4-4.0
1m
-9.6+5.9-15.5+1.7-11.3
2m
-13.4+4.8-18.2+3.0-16.5
3m
-7.5pendingpending-2.4-5.1
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 162Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Hester Biosciences reported Q1 FY27 results. Standalone revenue rose 14% to INR 726.60M and PAT jumped 88% to INR 147.11M, driven by 48% growth in Poultry Healthcare. Animal Healthcare fell 50% due to government tender delays. Consolidated revenue declined 8% to INR 772.44M, but PAT surged 459% to INR 967.32M, boosted by a one-time exceptional gain of INR 853.49M from Gates Foundation loan amendment at Hester Africa.

Likely market impact

Solid standalone results with margin expansion. Consolidated PAT jump is from a one-time accounting gain, not core operations. Watch Animal Healthcare.